Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK2 | P24941 | 10/20 | 0.38 |
| ▸ | CCND1 | P24385 | 9/20 | 0.38 |
| ▸ | CCNE1 | P24864 | 8/20 | 0.38 |
| ▸ | CDK6 | Q00534 | 7/20 | 0.38 |
| ▸ | CDK4 | P11802 | 5/20 | 0.38 |
| ▸ | TLR7 | Q9NYK1 | 4/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | TLR8 | Q9NR97 | 4/20 | 0.32 |
| ▸ | SRC | P12931 | 2/20 | 0.31 |
| ▸ | CDK1 | P06493 | 2/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.31 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.30 |
| ▸ | CDK9 | P50750 | 1/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4305036 | 0.89 | CCNE1 (0.38) | CDK2CCND1CCNE1CDK6CDK4 | |
| SCHEMBL13663022 | 0.86 | CCND1 (0.35) | CDK2CCND1CCNE1CDK6CDK4 | |
| SCHEMBL13663014 | 0.86 | TLR7 (0.37) | TLR7TLR8NUDT1 | |
| SCHEMBL5806536 | 0.86 | TLR7 (0.37) | TLR7TLR8NUDT1 | |
| SCHEMBL13663012 | 0.85 | TLR7 (0.36) | TLR7TLR8NUDT1 | |
| SCHEMBL5806666 | 0.85 | CDK1 (0.36) | CDK2CCND1CDK4TLR7TLR8 | |
| SCHEMBL4302882 | 0.83 | TLR7 (0.43) | TLR7TLR8NUDT1 | |
| SCHEMBL6281877 | 0.81 | TLR7 (0.33) | CDK2CCND1CCNE1CDK6CDK4 | |
| SCHEMBL6281876 | 0.80 | TLR7 (0.38) | CDK2CCND1CCNE1CDK6CDK4 | |
| SCHEMBL4296141 | 0.77 | TLR7 (0.34) | TLR7TLR8NUDT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090270443-A1 | 1-AMINO IMIDAZO-CONTAINING COMPOUNDS AND METHODS | COLEY PHARMACEUTICAL GROUP, INC. | 2009-10-29 | — | — | US | disclosed |
| US-20090270443-A1 | 1-AMINO IMIDAZO-CONTAINING COMPOUNDS AND METHODS | COLEY PHARMACEUTICAL GROUP, INC. | 2009-10-29 | — | — | US | disclosed |
| US-20090270443-A1 | 1-AMINO IMIDAZO-CONTAINING COMPOUNDS AND METHODS | COLEY PHARMACEUTICAL GROUP, INC. | 2009-10-29 | — | — | US | disclosed |
| WO-2006026760-A2 | 1-AMINO IMIDAZO-CONTAINING COMPOUNDS AND METHODS | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2006-03-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090270443-A1 | 1-AMINO IMIDAZO-CONTAINING COMPOUNDS AND METHODS | IL2, IL4I1, IFNG | CDK2 438/4885CCND1 2212/4885CCNE1 1972/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.